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Abstract
Background: Ethyl pyruvate (EP) was recently identified as an experimental therapeutic agent in
a wide variety of model systems for inflammation-mediated tissue and cellular injury.
Objective: To evaluate the effect of ethyl EP on improving the survival in mice with LPS-induced
acute lung injury (ALI).
Methods: ALI was induced by administering lipopolysaccharide (LPS) intratracheally. The mice
were treated intraperitoneally (i.p.) with 100, 50 and 10 mg/kg EP immediately before intratracheal
instillation of LPS, and 100 mg/kg EP was administered 0, 12, 24 and 48 hours after induction of ALI.
The mortality rate was recorded and analyzed by the Kaplan-Meier method. Serum tumor necrosis
factor (TNF)-, interleukin (IL) -6 and IL-1  were measured in bronchial alveolar lavage fluid using
an enzyme-linked immunosorbent assay. High-mobility group box 1 levels were measured by
Western immunoblotting.
Results: Treatment with EP significantly inhibited the release of HMGB1, TNF-, IL-6 and IL-1
into bronchoalveolar lavage (BAL) fluids of ALI mice, and reduced the permeability index of the
injured lung. High EP doses reduced the mortality from ALI and the permeability index (100 mg/kg
and 50 mg/kg EP versus control; P < 0.0001). Early administration of high-dose EP significantly
increased survival rate (0, 12 and 24 h versus control; P < 0.0001, P < 0.0001 and P = 0.01
respectively by log-rank test). There was no survival advantage when EP was initiated at 48 h.
Conclusion: Ethyl pyruvate improves survival and reduces the lung permeability index in mice with
LPS-induced ALI.
Introduction
Despite significant advances in understanding the patho-
genesis of acute lung injury (ALI) and its management, the
mortality rate from ALI remains unacceptably high [1,2].
It is well known that the pathogenesis of ALI is mediated
by pro-inflammatory cytokines, including tumor necrosis
factor (TNF)-, interleukin (IL)-1, IL-6 and high-mobil-
ity group box (HMGB) 1, which are released from macro-
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phages, neutrophils and other cells of the innate immune
system [3,4]. However, in two large clinical trails, admin-
istration of a monoclonal antibody against human TNF-
(TNF- MAb) and a recombinant human IL-1 (rhIL-1ra)
receptor antagonist failed to prolong survival in patients
with sepsis syndrome [5,6].
HMGB1 is a late mediator of lethal systemic inflamma-
tion in animal models of cytokine-mediated disease. It is
released by macrophages only after a delay of 12-18 h dur-
ing endotoxemia [7]. Anti-HMGB1 antibodies protect
against the lethal effects of LPS-induced endotoxemia in
mice when administered 2 h after the onset of endotox-
emia [7]. HMGB1 stimulates the release of TNF-, IL-1
and other inflammatory cytokines from macrophages and
pituicytes, and mediates ALI and lethality [8,9]. Moreover,
in patients with severe infection, increased serum HMGB-
1 levels correlated with non-survival [7]. These results sug-
gest that HMGB1 is an important mediator in ALI and that
its inhibition may be a key to improving clinical out-
comes.
Ethyl pyruvate (EP) is a simple derivative of the endog-
enous metabolite pyruvic acid. Pyruvic acid is an end
product of glycolysis, but it is also a potent antioxidant
and free-radical scavenger. EP has been shown to improve
survival and ameliorate organ dysfunction in a wide vari-
ety of animal models of severe sepsis [10], hemorrhagic
shock [11], ischemia/reperfusion-induced intestinal
mucosal injury [12], and ileus induced by bowel manipu-
lation in mice [13]. EP inhibits lipopolysaccharide (LPS)-
induced NF-B activation in cultured RAW264.7 murine
macrophage-like cells, and reduces HMGB1 release and
TNF- gene expression both in vitro and in vivo [10-13].
Therefore, we reasoned that EP might also be protective in
established ALI, depending on inhibition of early and late
inflammatory cytokines. The present study was designed
to evaluate whether EP could be beneficial in a mouse
model of LPS-induced ALI.
Materials and methods
Animals and Materials
Adult male BALB/c mice (22-25 g) were allowed to accli-
matize for one week housed at 25°C on a 12-h light/12-h
dark cycle; all animals were allowed free access to water
and standard laboratory chow. All studies were conducted
in accordance with the committee of Shandong University
School of Medicine on the use and care of animals. The
protocols were also approved by the Institutional Animal
Care and Use Committee of Shandong University Qilu
Hospital. All chemicals were purchased from Sigma-
Aldrich (St. Louis, MO). Ethyl pyruvate solution was pre-
pared as 28 mM EP, 130 mM NaCl, 4 mM KCl, 2.7 mM
CaCl2 (pH 7.0).
Animal Model of Lung injury
Before the induction of ALI, the mice were fasted over-
night but allowed free access to water, then anesthetized
with ketamine (100 mg/kg, i.m.) and xylazine (10 mg/kg,
i.m.). To create the lung injury, 50 g LPS from Escherichia
coli (serotype O111:B4; Sigma-Aldrich) in 50 l PBS was
given intratracheally. Sham-operated mice underwent the
same procedure with intratracheal injection of 50 l PBS
without LPS. To retrieve bronchoalveolar lavage (BAL)
fluids, the airways were flushed with 1.0 ml PBS, BAL flu-
ids were collected, and the permeability index as a quan-
titative marker of vascular leakage was determined as
previously described [14]. In brief, bovine serum albumin
(BSA) was labeled with 125I by the chloramine T method.
A trace amount of 125I-BSA was added to unlabeled BSA (5
mg/ml in PBS), and 200 l of this solution was injected
intravenously. Four hours later, the mice were euthanized
with ketamine and blood was collected from the inferior
vena cava. The thorax was opened, the left atrium was
incised, and the lung was perfused in situ with PBS via the
pulmonary artery. The flushed lungs were removed and
the permeability index (indicating the extent of pulmo-
nary leakage) was determined using a gamma counter and
expressed as the ratio of counts per min (cpm) in the
whole lung to radioactivity in 100 l of blood. BAL fluids
were collected and the permeability index was calculated
12 h after ALI induction unless otherwise noted.
Experimental Protocol
In the first experiment, 50 LPS-induced ALI mice were
divided randomly into two groups (n = 25, each group).
EP was administered intraperitoneally (i.p.) at 100 mg/kg
immediately before intratracheal instillation of LPS, and
control mice received the same dose of vehicle. HMGB1,
TNF-, IL-1 and IL-6 were measured in BAL fluids and
the permeability indices were calculated.
The second experiment was designed to determine the
effect on mouse survival of treatment with different doses
of EP (100, 50 and 10 mg/kg) starting immediately before
intratracheal LPS instillation. Four separate groups of
mice (n = 30, each group) were used for this study. Among
the 30 mice in each group, 20 were used to record mortal-
ity up to a week after the procedure and 10 were killed at
12 h to calculate the permeability index. The mice in these
groups were treated with EP at 100, 50 and 10 mg/kg/d
(i.p.), and the control mice received the same dose of
vehicle until the end of the study. Mortality was recorded
up to a week after the procedure (n = 20). Mice (n = 10)
were killed and the permeability indices were calculated.
In the third experiment, the experimental and control
mice were divided randomly into four treatment groups
(n = 20, each group). EP was administered at the same
dose (100 mg/kg/d, i.p.), and control mice received theRespiratory Research 2009, 10:91 http://respiratory-research.com/content/10/1/91
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same volume of vehicle beginning at four different time
points (0, 12, 24 and 48 h after LPS instillation) until the
end of study. Mortality was recorded up to a week after the
injection.
Cytokine Measurements
The concentrations of TNF-, IL-6 and IL-1 were meas-
ured using commercially available enzyme-linked immu-
nosorbent assay kits (R&D Systems, Minneapolis, MN)
according to the manufacturer's instructions. The sensitiv-
ities for TNF-, IL-6 and IL-1 were 15 pg/ml, 5 pg/ml and
5 pg/ml, respectively. Levels of HMGB1 were measured by
Western immunoblotting as described by Wang et al. [7].
In brief, serum samples were ultrafiltered with Centricon
100 (Amicon, Millipore, Bedford, MA) to clear them of
cell debris and macromolecular complexes, then concen-
trated 15-fold with Centricon YM-30 and separated on
12% sodium dodecyl sulfate-polyacrylamide gels. The
separated proteins were transferred to an immunoblot
polymembrane (Bio-Rad, Hercules, Calif), and HMGB1
was measured using polyclonal anti-HMGB1 antibodies
(Santa Cruz, America, 1:500 dilution) and secondary anti-
rabbit antibodies linked to horseradish peroxidase (Amer-
sham Pharmacia, Buckinghamshire, UK). Standard curves
were constructed using r-HMGB1 (Sigma-Aldrich Chemi-
cal), and the intensity of the 30-kd band was measured by
densitometry.
Statistical Analysis
Data are presented as mean ± SEM unless otherwise indi-
cated. Differences between treatment groups were deter-
mined by Student's t test or 1-way analysis of variance
(ANOVA) followed by the least-significant difference test,
or Fisher's exact test. In the mortality study, time-to-sur-
vival data were analyzed by the Kaplan-Meier method and
compared with the log-rank test; P < 0.05 was considered
statistically significant.
Results
The effect of ethyl pyruvate on pro-inflammatory
cytokines in BAL fluids and permeability index of experi-
mental ALI mice
To determine the levels of pro-inflammatory cytokines in
BAL fluids, we flushed the airways with 1.0 ml PBS and
collected the BAL fluids 12 h after ALI induction. As
shown in Table 1, levels of the cytokines HMGB1, TNF-,
IL-6 and IL-1 were substantially elevated in BAL fluids
from LPS-induced ALI mice (versus controls; P < 0.001).
Treatment with EP (100 mg/kg, i.p., immediately before
intratracheal LPS instillation) significantly inhibited the
release of HMGB1, TNF-, IL-6 and IL-1 into the BAL flu-
ids of ALI mice (Table 1), indicating that EP prevented
LPS-induced ALI by attenuating the release of early (TNF-
, IL-6, and IL-1) and late (HMGB1) systemic pro-
inflammatory cytokines associated with lethality. As
shown in Fig. 1, EP reduced the permeability indices of
the injured lungs (Fig. 1).
Administration of high dose EP prevents the lethality of
ALI and reduces the permeability index
To evaluate the protective effect of EP against lethality in
LPS-induced ALI mice, the mice received three different
doses of EP (100, 50 and 10 mg/kg/d. i.p.) starting imme-
diately before intratracheal LPS instillation. The results
showed that the high EP dose (100 mg/kg/d) protected
against ALI lethality (survival in 100 mg/kg/d and 50 mg/
kg/d of EP versus survival in vehicle-treated controls; P <
0.0001 and P = 0.02 respectively), but the effect was dose
dependent; the low dose failed to protect significantly
against death (survival in 10 mg/kg/d of EP versus survival
in vehicle-treated controls; P = 0.81) (Fig. 2). Also, there
was a dose-dependent reduction in the permeability index
(100 mg/kg/d and 50 mg/kg/d EP versus vehicle-treated
control, P < 0.0001; 10 mg/kg/d versus vehicle-treated
control, P = 1.00; Fig. 3).
Early administration of high dose EP prevents ALI
lethality
To assess the therapeutic efficacy of early EP treatment
against ALI, EP was administered at different time points
(0, 12, 24 and 48 h after induction of ALI) at the same sin-
gle dose of 100 mg/kg/d, i.p. The results showed that early
administration of high dose EP (0, 12 or 24 h) signifi-
cantly increased survival rate in the mice (survival after
administration EP at 0, 12 and 24 h versus survival in
vehicle-treated controls; P < 0.0001, P < 0.0001 and P =
Table 1: Cytokine concentrations in BAL fluids of ALI mice
Cytokine Control ALI EP treatment Unit
HMGB1 37.8 ± 10.8 129.0 ± 22.8* 86.4.8 ± 22.4# ng/mL
TNF- 377.4 ± 94.8 1584.3 ± 379.0* 650.5 ± 190.4# pg/mL
IL-1 86.0 ± 18.2 308.2 ± 50.5* 181.6 ± 53.5# pg/mL
IL-6 82.9 ± 18.1 914.6 ± 103.5* 434.1 ± 126.0# pg/mL
* P < 0.001 as compared with control group # P < 0.001 as compared with ALI groupRespiratory Research 2009, 10:91 http://respiratory-research.com/content/10/1/91
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0.01, respectively) (Fig. 4). However, no survival advan-
tage occurred when EP was initiated at 48 h (survival after
EP administration at 48 h versus survival in vehicle-
treated controls; P = 0.75) (Fig. 4). Moreover, the animals
treated with EP beginning at 0, 12, and 24 h were signifi-
cantly more active and alert and fed more rapidly than
either the animals with treatment beginning at 48 h or
controls treated with vehicle.
Discussion
Acute lung injury (ALI) is an important problem in
humans and its pathogenesis is poorly understood. To
investigate the molecular mechanisms of ALI, various
experimental models have been used; intratracheal
administration of LPS induces an ideal model because it
results in lung injury without causing systemic inflamma-
tion and multi-organ failure. Moreover, the LPS-induced
ALI model results in microvascular injury and diffuse alve-
olar damage with intrapulmonary hemorrhage, edema
and fibrin deposition, which are also features of patients
with ALI and acute respiratory distress syndrome (ARDS)
[15,16].
In this present study, the levels of both early (TNF-, IL-
1 and IL-6) and late (HMGB1) cytokines in BAL fluids
increased in mice with ALI 12 h after induction. Ethyl
pyruvate (EP), an experimental pharmacological agent,
significantly inhibited the systemic release of these
cytokines, which mediate the lethality of ALI and systemic
The effect of ethyl pyruvate on permeability index in ALI Figure 1
The effect of ethyl pyruvate on permeability index in 
ALI. *P < 0.0001 versus ethyl pyruvate treatment group.
Administration of high EP dose prevents the lethality of ALI Figure 2
Administration of high EP dose prevents the lethality of ALI. Survival curves (100 mg/kg/d and 50 mg/kg/d EP versus 
survival in vehicle-treated controls; P < 0.0001 and P = 0.02 by log-rank test, respectively; 10 mg/kg/d EP versus vehicle-treated 
controls; P = 0.81 by log-rank test).Respiratory Research 2009, 10:91 http://respiratory-research.com/content/10/1/91
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inflammation. Early administration of high-dose EP (0,
12, 24 h) significantly protected against ALI lethality.
However, low dose EP or delayed administration gave no
advantage in terms of survival. It is likely that pro-inflam-
matory cytokines, notably TNF-, IL-1 and IL-6, partici-
pate in the early development of inflammation; they have
been shown to play a crucial role in ALI and ARDS [17].
Persistent elevation of pro-inflammatory cytokines in
serum and BAL fluid in ALI or sepsis patients is associated
with a worse outcome [18]. Furthermore, instillation of
IL-1 and TNF- into the lungs leads to neutrophil accu-
mulation, interstitial edema and histological changes con-
sistent with inflammatory lung injury [17-19]. High
concentrations of TNF- are found in BAL fluids from
patients with sustained ALI and ARDS, and high levels of
IL-6 have been described in a number of acute conditions
such as burns, major surgery and sepsis [20]. In patients
with ALI and ARDS, non-survivors have significantly
higher BAL-fluid-to-plasma cytokine concentration ratios
than survivors [21], indicating the critical role of these
cytokines in mortality.
These results suggest that the levels of HMGB1 in BAL flu-
ids were greater in LPS-induced ALI mice than control
mice. Moreover, administration of EP reduced the late
mediator HMGB1. Unlike other pro-inflammatory
cytokines, HMGB1 is a "late-appearing" inflammatory
mediator, because its release during endotoxemia is
delayed in comparison with the rapid increase of early
pro-inflammatory cytokines such as IL-1, IL-6 and TNF-
 [7,10,22,23]. HMGB1 rose in the circulation starting at
8 h, increased until 16 h, and thereafter remained at a high
level until 36 h during endotoxemia [7]. Further study
showed that administration of anti-HMGB1 antibodies
reduced lethality from 100% to 30% [7]. Intratracheal
administration of HMGB1 produced acute inflammatory
lung injury, and anti-HMGB1 Abs decreased the migra-
tion of neutrophils to the lungs as well as lung edema in
endotoxin-induced acute lung inflammation [23]. Thus,
delayed release of HMGB1 can participate in the down-
stream development of lung injury, and HMGB1 may be
a distal mediator of acute inflammatory lung injury.
Ethyl pyruvate (EP), a very simple aliphatic ester derived
from pyruvic acid, has been shown to be an effective anti-
inflammatory agent in a wide variety of in vivo and in
vitro model systems of inflammation-mediated cellular or
tissue injury, including severe sepsis, hemorrhagic shock,
ischemia/reperfusion-induced intestinal mucosal injury,
and ileus induced by bowel manipulation in mice [10-
13,24,25]. EP increases survival and reduces circulating
levels of IL-6 [26]., and inhibits activation of NF-B in
Caco-2 human enterocyte-like cells stimulated with a mix-
ture of TNF- and IL-1 [27]. It blocks the secretion of
HMGB1 by LPS-stimulated RAW 264.7 cells and the
release of HMGB1 into the circulation in mice [10]. The
There was also a dose-dependent reduction in the permeability index (*# P < 0.0001 versus vehicle-treated control; $ P = 1.00  versus vehicle-treated control) Figure 3
There was also a dose-dependent reduction in the permeability index (*# P < 0.0001 versus vehicle-treated 
control; $ P = 1.00 versus vehicle-treated control).Respiratory Research 2009, 10:91 http://respiratory-research.com/content/10/1/91
Page 6 of 7
(page number not for citation purposes)
survival advantage was apparent even when EP was
administered 30 min before endotoxin infusion, and the
treatment began 24 h after the onset of disease [10]. The
molecular mechanism of EP action is to interfere with sig-
nal transduction through the p38 MAPK and NF-B path-
ways, and to target directly the p65 subunit of the
transcription factor [10,28]. EP inhibition of the p38
MAPK and NF-B signal transduction pathways effectively
induced the release of early (TNF-, IL-1 and IL-6) and
late (HMGB1) inflammatory mediators. Our data showed
that administration of EP even when initiated 24 h after
induction of ALI significantly increased survival, though
no survival advantage occurred when administration was
initiated at 48 h, when the levels of these cytokines had
decreased significantly; indicating that EP modulation of
HMGB1 and other inflammatory cytokines contributes to
the beneficial effects on survival.
Conclusion
In conclusion, EP decreased the release of pro-inflamma-
tory cytokines and improved survival in mice with LPS-
induced ALI. Thus, EP may be developed as a novel thera-
peutic adjunct in the treatment of ALI.
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